IRWDNasdaqPharmaceutical PreparationsFiscal year ends December 31
IRONWOOD PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.56+0.06 (+1.71%)
Close on Oct 19, 2026
- Market cap
- $595.16M
- P/E (TTM)
- 4.6
- Dividend yield
- –
IRONWOOD PHARMACEUTICALS INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q4 25 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | TTM Q4 22 | TTM Q3 22 | TTM Q2 22 | TTM Q1 22 | % of revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaborative arrangement, other agreements | $87.00K | $1.70M | $2.23M | $2.41M | $2.48M | $2.45M | $2.06M | $1.92M | $1.82M | $1.65M | $1.83M | $1.83M | 0.0% |
| Collaborative arrangements revenue | – | – | – | – | – | – | $427.28M | $417.13M | $410.60M | $420.38M | $415.49M | $421.65M | – |
By region
From the segment and revenue-disaggregation notes of Ironwood Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.